Mckesson Corp (MCK)
適正価値ファンダメンタル
79
株価
$853.81
時価総額
$99.84B
パート1 · 企業の価値
概要
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月19日 with claude-haiku-4-5 — shared with all users
McKesson's 10-K names Cencora as one of its two largest competitors: both are national full-line wholesalers distributing branded, generic and specialty drugs to the same U.S. pharmacy chains, health systems and physician practices.
The other of the two competitors McKesson names by name: Cardinal Health bids for the same U.S. drug-distribution contracts and also sells medical-surgical supplies to the same hospitals and surgery centers.
Henry Schein's own 10-K names McKesson as one of its two primary national competitors in the medical market, where both supply consumables and equipment to office-based physicians and dental practices.
Privately held national distributor of medical-surgical supplies, competing head-on with McKesson Medical-Surgical for hospital, surgery-centre and physician-office supply contracts.
Distributor of medical-surgical products to U.S. acute-care hospitals and health systems, bidding for the same supply-chain contracts as McKesson's Medical-Surgical Solutions segment.
Privately held regional full-line pharmaceutical wholesaler in the U.S. South, serving the independent pharmacies and regional hospital groups that McKesson also supplies.
貸借対照表と流動性
売上高
$410.98B
直近12か月（2026/6/30まで）
純利益
$4.59B
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$5.72B
自己資本合計
$-2.17B
負債合計
$84.10B
流動比率
0.89
利払い倍率
23.62
負債/EBITDA
1.80
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$911.16
現在株価
$853.81
安全マージン
+6.3%
適正価値レンジ
$662.92 - $1159.40
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
22.90
ROE
-219.2%
P/B レシオ
-
P/FCF
15.52
粗利益率
3.6%
ROIC
28.5%
収益性レーダー
価値創造（経済的モート）
ROIC
28.5%
WACC
7.3%
ROIC − WACC
+21.2 pp
ROICが資本コストを上回っています。企業は株主のために価値を創出しています。
ファンダメンタル分析基準
合格（19）
- EPS shows upward trend
- EPS CAGR 14.57%
- Price CAGR 20.17%
- ROIC 28.5%
- P/FCF 15.52
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 39.4%
- Revenue Growth 5Y 11.1%
- Analyst Consensus 79% Buy
- Earnings Surprise avg 2.9%
- Earnings Quality (OCF/NI) 1.49
- Share Dilution -3.1%
- Net Margin Trend 1.1% vs 0.8%
- Piotroski F-Score 7/9
不合格（4）
- Gross Margin 3.6%
- Operating Margin 1.6%
- Low reliance on intangibles
- DCF valuation (Overvalued)
データなし（5）
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-スコア
財務健全性が高い
利益の質
高品質：利益はキャッシュに裏付けられている
株式希薄化
株式を買い戻している。株主に友好的
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Brian S. Tyler Ph.D. | CEO & Chairman | 58 |
| Ms. Michele Lau J.D. | Executive VP & Chief Legal Officer | 49 |
| Ms. LeAnn B. Smith | Executive VP & Chief Human Resources Officer | 50 |
| Mr. Kenny K. Cheung | Executive VP & CFO | 43 |
| Mr. Napoleon B. Rutledge Jr. | Senior VP, Controller & Chief Accounting Officer | 52 |
| Paula Adkison | Senior Vice President of Corporate Finance, Investor Relations & Strategic Finance | - |
| Mr. Francisco J. Fraga | Executive VP, Chief Information Officer & CTO | 52 |
| Ms. Jeni Dominguez | Head of Investor Relations | - |
| Mr. Kirk Kaminsky | Executive VP & Group President of North American Pharmaceutical Services | - |
| Mr. Stanton J. McComb | President of Medical-Surgical | - |
監査リスク
9
取締役会リスク
6
報酬リスク
1
株主権利リスク
4
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for MCK, sourced from Markets Gazette.
- 6/3/2026NEUTRALMcKesson Unit Prices $2.25 Billion Leveraged Loan Ahead of IPO
McKesson Corp.'s medical-surgical unit has priced a $2.25 billion leveraged loan. This move precedes the unit's anticipated initial public offering (IPO). While the loan issuance itself is a financing activity, its direct impact on McKesson's stock price is neutral at this stage. The successful pricing indicates market appetite for the unit's debt, which could be a positive precursor to the IPO, but the primary focus remains on the upcoming equity offering rather than the debt itself for immediate trading signals.
- 4/8/2026POSITIVEHere's How Much $100 Invested In McKesson 20 Years Ago Would Be Worth Today
An investment of $100 in McKesson Corporation (MCK) twenty years ago would have grown to approximately $1,640 today, representing a significant 16.4x return. This performance indicates a strong compound annual growth rate (CAGR) over the past two decades, outperforming many market benchmarks. The sustained growth suggests effective business strategy, operational efficiency, and favorable market positioning within the healthcare distribution sector. For investors, this historical data highlights McKesson's long-term value creation potential and its resilience through various economic cycles.
via Markets Gazette